Overview

* Axsome Q3 2025 net product revenue grows 63% yr/yr to $171 mln

* AUVELITY Q3 2025 sales rise 69% yr/yr to $136.1 mln

* Company submits sNDA for AXS-05 in Alzheimer's agitation to FDA

Outlook

* Axsome plans to initiate multiple Phase 3 trials in 4Q 2025

* Company expects cash to fund operations into cash flow positivity

* Axsome submitted sNDA for AXS-05 in Alzheimer's disease agitation

Result Drivers

* AUVELITY SALES - AUVELITY sales increased 69% yr/yr to $136.1 mln, driven by expanded payer coverage and increased prescriptions

* SUNOSI REVENUE - SUNOSI revenue grew 35% yr/yr to $32.8 mln, supported by increased prescriptions and royalty revenue

* SYMBRAVO LAUNCH - SYMBRAVO generated $2.1 mln in its first full quarter post-launch, contributing to overall revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$47.22

Income mln

Q3 $217.10

Operatin mln

g

Expenses

Q3 -$46.10

Operatin mln

g Income

Q3 -$47.22

Pretax mln

Profit

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)